Yahoo · Sep 3, 2026
Pulmonx Shares Fall Following Recent Gains
Pulmonx (NASDAQ:LUNG) shares fell 10. 1% to $2.
LU
NASDAQ · LUNG
Pulmonx Corporation
Healthcare · Medical - Devices
$1.85
Up+$0.00 (+0.00%)
Updated Sep 13, 2026, 6:37 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 103.73M
- P/E ratio
- -1.78
- Dividend yield
- 0.00%
- 52-week range
- $1.13 – $2.59
- Volume
- 204.93K
- Avg. volume
- 2.59M
Price performance
LUNG price history
1M range · 19 trading sessions · Daily adjusted prices
LUNG closed at $1.85 after 19 trading sessions, down 17.04% for the selected period.
- Last close
- $1.85
- Period change
- -17.04%
- Period low
- $1.85
- Period high
- $2.50
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.94 | $2.005 | $1.815 | $1.85 | 204.93K |
| Sep 10, 2026 | $1.90 | $1.91 | $1.815 | $1.85 | 479.33K |
| Sep 9, 2026 | $2.12 | $2.16 | $1.98 | $1.98 | 451.94K |
| Sep 8, 2026 | $2.18 | $2.195 | $2.07 | $2.08 | 308.08K |
| Sep 4, 2026 | $2.26 | $2.30 | $2.19 | $2.21 | 220.38K |
| Sep 3, 2026 | $2.27 | $2.33 | $2.25 | $2.26 | 284.13K |
| Sep 2, 2026 | $2.24 | $2.435 | $2.24 | $2.28 | 407.39K |
| Sep 1, 2026 | $2.26 | $2.43 | $2.23 | $2.24 | 525.19K |
| Aug 31, 2026 | $2.34 | $2.39 | $2.295 | $2.38 | 320.17K |
| Aug 28, 2026 | $2.42 | $2.5117 | $2.38 | $2.38 | 277.21K |
| Aug 27, 2026 | $2.50 | $2.585 | $2.41 | $2.42 | 268.63K |
| Aug 26, 2026 | $2.54 | $2.59 | $2.37 | $2.50 | 313.7K |
| Aug 25, 2026 | $2.29 | $2.52 | $2.2785 | $2.50 | 581.67K |
| Aug 24, 2026 | $2.24 | $2.35 | $2.21 | $2.28 | 393.83K |
| Aug 21, 2026 | $2.30 | $2.35 | $2.195 | $2.26 | 610.2K |
| Aug 20, 2026 | $2.28 | $2.39 | $2.28 | $2.30 | 395.43K |
| Aug 19, 2026 | $2.26 | $2.365 | $2.24 | $2.31 | 336.97K |
| Aug 18, 2026 | $2.20 | $2.39 | $2.20 | $2.26 | 254K |
| Aug 17, 2026 | $2.39 | $2.42 | $2.165 | $2.23 | 440.17K |
Latest LUNG news
The latest Smart Investors Daily articles mentioning LUNG.
Stock researchCompany · Overview
LUNG research
Overview
Company profile and research snapshot.
Company profile
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $3.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 30, 2026 | D. Boral Capital | Buy | — |
| Mar 5, 2026 | D. Boral Capital | Buy | — |
| Mar 5, 2026 | Canaccord Genuity | Buy | — |
| Feb 20, 2026 | D. Boral Capital | Buy | — |
| Nov 13, 2025 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 1, 2026
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company’s Board of Directors
Yahoo · Aug 27, 2026
Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare ConferenceFormat: 1x1 meetingsDate: Wednesday, September 9Location: Boston, MA Lake Street Best Ideas Growth (BIG10) ConferenceFormat: 1x1 meetingsDate: Thursday, September 10Location: New York, NY About
Yahoo · Aug 3, 2026
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
